-
Je něco špatně v tomto záznamu ?
Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study
N. Bizzarri, D. Querleu, L. Dostálek, LRCW. van Lonkhuijzen, D. Giannarelli, A. Lopez, S. Salehi, A. Ayhan, SH. Kim, DI. Ortiz, J. Klat, F. Landoni, R. Pareja, R. Manchanda, J. Kosťun, PT. Ramirez, MM. Meydanli, D. Odetto, R. Laky, I. Zapardiel,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu multicentrická studie, časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
P30 CA008748
NCI NIH HHS - United States
- MeSH
- hysterektomie škodlivé účinky MeSH
- lidé MeSH
- nádory děložního čípku * patologie MeSH
- přežití bez známek nemoci MeSH
- retrospektivní studie MeSH
- spinocelulární karcinom * patologie MeSH
- staging nádorů MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: International guidelines recommend tailoring the radicality of hysterectomy according to the known preoperative tumor characteristics in patients with early-stage cervical cancer. OBJECTIVE: This study aimed to assess whether increased radicality had an effect on 5-year disease-free survival in patients with early-stage cervical cancer undergoing radical hysterectomy. The secondary aims were 5-year overall survival and pattern of recurrence. STUDY DESIGN: This was an international, multicenter, retrospective study from the Surveillance in Cervical CANcer (SCCAN) collaborative cohort. Patients with the International Federation of Gynecology and Obstetrics 2009 stage IB1 and IIA1 who underwent open type B/C1/C2 radical hysterectomy according to Querleu-Morrow classification between January 2007 and December 2016, who did not undergo neoadjuvant chemotherapy and who had negative lymph nodes and free surgical margins at final histology, were included. Descriptive statistics and survival analyses were performed. Patients were stratified according to pathologic tumor diameter. Propensity score match analysis was performed to balance baseline characteristics in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy. RESULTS: A total of 1257 patients were included. Of note, 883 patients (70.2%) underwent nerve-sparing radical hysterectomy, and 374 patients (29.8%) underwent non-nerve-sparing radical hysterectomy. Baseline differences between the study groups were found for tumor stage and diameter (higher use of non-nerve-sparing radical hysterectomy for tumors >2 cm or with vaginal involvement; P<.0001). The use of adjuvant therapy in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy was 27.3% vs 28.6%, respectively (P=.63). Five-year disease-free survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 90.1% (95% confidence interval, 87.9-92.2) vs 93.8% (95% confidence interval, 91.1-96.5), respectively (P=.047). Non-nerve-sparing radical hysterectomy was independently associated with better disease-free survival at multivariable analysis performed on the entire cohort (hazard ratio, 0.50; 95% confidence interval, 0.31-0.81; P=.004). Furthermore, 5-year overall survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 95.7% (95% confidence interval, 94.1-97.2) vs non-nerve-sparing 96.5% (95% confidence interval, 94.3-98.7), respectively (P=.78). In patients with a tumor diameter ≤20 mm, 5-year disease-free survival was 94.7% in nerve-sparing radical hysterectomy vs 96.2% in non-nerve-sparing radical hysterectomy (P=.22). In patients with tumors between 21 and 40 mm, 5-year disease-free survival was 90.3% in non-nerve-sparing radical hysterectomy vs 83.1% in nerve-sparing radical hysterectomy (P=.016) (no significant difference in the rate of adjuvant treatment in this subgroup, P=.47). This was confirmed after propensity match score analysis (balancing the 2 study groups). The pattern of recurrence in the propensity-matched population did not demonstrate any difference (P=.70). CONCLUSION: For tumors ≤20 mm, no survival difference was found with more radical hysterectomy. For tumors between 21 and 40 mm, a more radical hysterectomy was associated with improved 5-year disease-free survival. No difference in the pattern of recurrence according to the extent of radicality was observed. Non-nerve-sparing radical hysterectomy was associated with better 5-year disease-free survival than nerve-sparing radical hysterectomy after propensity score match analysis.
Department of Gynaecological Oncology Barts Health NHS Trust London United Kingdom
Department of Gynecologic Oncology Barretos Cancer Hospital Barretos Sao Paulo Brazil
Department of Gynecologic Oncology Instituto Nacional de Cancerología Bogotá Colombia
Department of Gynecological Surgery National Institute of Neoplastic Diseases Lima Peru
Department of Gynecology Medical University of Graz Graz Austria
Department of Pelvic Cancer Karolinska University Hospital Stockholm Sweden
Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden
Faculty of Medicine University Hospital Brno Masaryk University Brno Czechia
Gynecologic Oncology Unit La Paz University Hospital IdiPAZ Madrid Spain
Gynecology Oncology Center National Institute of Cancerology Mexico Mexico City Mexico
Houston Methodist Hospital Houston TX
IRCCS Fondazione San Gerardo Università Milano Bicocca Monza Italy
Memorial Sloan Kettering Cancer Center New York NY
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016148
- 003
- CZ-PrNML
- 005
- 20231026110316.0
- 007
- ta
- 008
- 231013s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ajog.2023.06.030 $2 doi
- 035 __
- $a (PubMed)37336255
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bizzarri, Nicolò $u Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. Electronic address: nicolo.bizzarri@yahoo.com
- 245 10
- $a Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study / $c N. Bizzarri, D. Querleu, L. Dostálek, LRCW. van Lonkhuijzen, D. Giannarelli, A. Lopez, S. Salehi, A. Ayhan, SH. Kim, DI. Ortiz, J. Klat, F. Landoni, R. Pareja, R. Manchanda, J. Kosťun, PT. Ramirez, MM. Meydanli, D. Odetto, R. Laky, I. Zapardiel, V. Weinberger, R. Dos Reis, L. Pedone Anchora, K. Amaro, H. Akilli, NR. Abu-Rustum, RA. Salcedo-Hernández, V. Javůrková, CH. Mom, G. Scambia, H. Falconer, D. Cibula
- 520 9_
- $a BACKGROUND: International guidelines recommend tailoring the radicality of hysterectomy according to the known preoperative tumor characteristics in patients with early-stage cervical cancer. OBJECTIVE: This study aimed to assess whether increased radicality had an effect on 5-year disease-free survival in patients with early-stage cervical cancer undergoing radical hysterectomy. The secondary aims were 5-year overall survival and pattern of recurrence. STUDY DESIGN: This was an international, multicenter, retrospective study from the Surveillance in Cervical CANcer (SCCAN) collaborative cohort. Patients with the International Federation of Gynecology and Obstetrics 2009 stage IB1 and IIA1 who underwent open type B/C1/C2 radical hysterectomy according to Querleu-Morrow classification between January 2007 and December 2016, who did not undergo neoadjuvant chemotherapy and who had negative lymph nodes and free surgical margins at final histology, were included. Descriptive statistics and survival analyses were performed. Patients were stratified according to pathologic tumor diameter. Propensity score match analysis was performed to balance baseline characteristics in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy. RESULTS: A total of 1257 patients were included. Of note, 883 patients (70.2%) underwent nerve-sparing radical hysterectomy, and 374 patients (29.8%) underwent non-nerve-sparing radical hysterectomy. Baseline differences between the study groups were found for tumor stage and diameter (higher use of non-nerve-sparing radical hysterectomy for tumors >2 cm or with vaginal involvement; P<.0001). The use of adjuvant therapy in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy was 27.3% vs 28.6%, respectively (P=.63). Five-year disease-free survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 90.1% (95% confidence interval, 87.9-92.2) vs 93.8% (95% confidence interval, 91.1-96.5), respectively (P=.047). Non-nerve-sparing radical hysterectomy was independently associated with better disease-free survival at multivariable analysis performed on the entire cohort (hazard ratio, 0.50; 95% confidence interval, 0.31-0.81; P=.004). Furthermore, 5-year overall survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 95.7% (95% confidence interval, 94.1-97.2) vs non-nerve-sparing 96.5% (95% confidence interval, 94.3-98.7), respectively (P=.78). In patients with a tumor diameter ≤20 mm, 5-year disease-free survival was 94.7% in nerve-sparing radical hysterectomy vs 96.2% in non-nerve-sparing radical hysterectomy (P=.22). In patients with tumors between 21 and 40 mm, 5-year disease-free survival was 90.3% in non-nerve-sparing radical hysterectomy vs 83.1% in nerve-sparing radical hysterectomy (P=.016) (no significant difference in the rate of adjuvant treatment in this subgroup, P=.47). This was confirmed after propensity match score analysis (balancing the 2 study groups). The pattern of recurrence in the propensity-matched population did not demonstrate any difference (P=.70). CONCLUSION: For tumors ≤20 mm, no survival difference was found with more radical hysterectomy. For tumors between 21 and 40 mm, a more radical hysterectomy was associated with improved 5-year disease-free survival. No difference in the pattern of recurrence according to the extent of radicality was observed. Non-nerve-sparing radical hysterectomy was associated with better 5-year disease-free survival than nerve-sparing radical hysterectomy after propensity score match analysis.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory děložního čípku $x patologie $7 D002583
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a hysterektomie $x škodlivé účinky $7 D007044
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 12
- $a spinocelulární karcinom $x patologie $7 D002294
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Querleu, Denis $u Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Dostálek, Lukáš $u First Faculty of Medicine, Department of Obstetrics and Gynecology, Gynecologic Oncology Center, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group), Prague, Czech Republic
- 700 1_
- $a van Lonkhuijzen, Luc R C W $u Center for Gynaecologic Oncology Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- 700 1_
- $a Giannarelli, Diana $u Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Lopez, Aldo $u Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru
- 700 1_
- $a Salehi, Sahar $u Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Ayhan, Ali $u Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Baskent University School of Medicine, Ankara, Turkey
- 700 1_
- $a Kim, Sarah H $u Memorial Sloan Kettering Cancer Center, New York, NY
- 700 1_
- $a Ortiz, David Isla $u Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico City, Mexico
- 700 1_
- $a Klat, Jaroslav $u Faculty of Medicine, Department of Obstetrics and Gynecology, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Landoni, Fabio $u IRCCS Fondazione San Gerardo - Università Milano Bicocca, Monza, Italy
- 700 1_
- $a Pareja, Rene $u Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá, Colombia
- 700 1_
- $a Manchanda, Ranjit $u Wolfson Institute of Population Health, Barts Cancer Centre, Queen Mary University of London, and Barts Health NHS Trust, London, United Kingdom; Department of Gynaecological Oncology, Barts Health NHS Trust, London, United Kingdom; Faculty of Public Health and Policy, Department of Health Services Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 700 1_
- $a Kosťun, Jan $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic
- 700 1_
- $a Ramirez, Pedro T $u Houston Methodist Hospital, Houston, TX
- 700 1_
- $a Meydanli, Mehmet M $u Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health and Research Hospital, University of Health Sciences, Ankara, Turkey
- 700 1_
- $a Odetto, Diego $u Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina
- 700 1_
- $a Laky, Rene $u Department of Gynecology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Zapardiel, Ignacio $u Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain
- 700 1_
- $a Weinberger, Vit $u Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia
- 700 1_
- $a Dos Reis, Ricardo $u Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
- 700 1_
- $a Pedone Anchora, Luigi $u Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Amaro, Karina $u Oncology Unit, Cayetano Heredia Hospital, Lima, Peru
- 700 1_
- $a Akilli, Huseyin $u Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Baskent University School of Medicine, Ankara, Turkey
- 700 1_
- $a Abu-Rustum, Nadeem R $u Memorial Sloan Kettering Cancer Center, New York, NY
- 700 1_
- $a Salcedo-Hernández, Rosa A $u Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico City, Mexico
- 700 1_
- $a Javůrková, Veronika $u Faculty of Medicine, Department of Obstetrics and Gynecology, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Mom, Constantijne H $u Center for Gynaecologic Oncology Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- 700 1_
- $a Scambia, Giovanni $u Unità Operativa Complessa Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Falconer, Henrik $u Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Cibula, David $u First Faculty of Medicine, Department of Obstetrics and Gynecology, Gynecologic Oncology Center, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group), Prague, Czech Republic
- 773 0_
- $w MED00000270 $t American journal of obstetrics and gynecology $x 1097-6868 $g Roč. 229, č. 4 (2023), s. 428.e1-428.e12
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37336255 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110311 $b ABA008
- 999 __
- $a ok $b bmc $g 1999961 $s 1202510
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 229 $c 4 $d 428.e1-428.e12 $e 20230617 $i 1097-6868 $m American journal of obstetrics and gynecology $n Am J Obstet Gynecol $x MED00000270
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20231013
